Cornea · 2011
Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
You In-Cheon, Im Seong-Kyu, Lee Seung-Hyun, Yoon Kyung-Chul
Аннотация
PURPOSE: To investigate the efficacy of combined photodynamic therapy with verteporfin and subconjunctival injection of bevacizumab for the treatment of patients with corneal neovascularization.
METHODS: Twelve eyes of 12 patients with stable corneal neovascularization who were refractory to conventional treatment were treated with photodynamic therapy with verteporfin (6 mg/m) and subconjunctival injection of bevacizumab (2.5 mg/0.1 mL). Anterior segment photography was performed before and after treatment. Best-corrected visual acuity, cumulative length of corneal blood vessels, and area of corneal neovascularization were measured.
RESULTS: From 1 week to 1 month after treatment, all eyes showed a notable decrease in corneal neovascularization and evidence of vascular thrombosis. At the 6-month and 1-year follow-ups, complete vascular occlusion was achieved in 8 eyes (66.7%) and partial occlusion was achieved in 3 eyes (25.0%). One eye (8.3%) showed revascularization after temporary occlusion. No ocular complications or systemic events developed.
CONCLUSIONS: Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab seems to be effective for the treatment of corneal neovascularization.
METHODS: Twelve eyes of 12 patients with stable corneal neovascularization who were refractory to conventional treatment were treated with photodynamic therapy with verteporfin (6 mg/m) and subconjunctival injection of bevacizumab (2.5 mg/0.1 mL). Anterior segment photography was performed before and after treatment. Best-corrected visual acuity, cumulative length of corneal blood vessels, and area of corneal neovascularization were measured.
RESULTS: From 1 week to 1 month after treatment, all eyes showed a notable decrease in corneal neovascularization and evidence of vascular thrombosis. At the 6-month and 1-year follow-ups, complete vascular occlusion was achieved in 8 eyes (66.7%) and partial occlusion was achieved in 3 eyes (25.0%). One eye (8.3%) showed revascularization after temporary occlusion. No ocular complications or systemic events developed.
CONCLUSIONS: Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab seems to be effective for the treatment of corneal neovascularization.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumabCombined Modality TherapyConjunctivaCorneal NeovascularizationFemaleFollow-Up StudiesHumansInjectionsMaleMiddle AgedPhotochemotherapyPhotosensitizing AgentsPilot ProjectsPorphyrinsProspective StudiesTreatment OutcomeVascular Endothelial Growth Factor AVerteporfinVisual AcuityYoung Adult